Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
14/09/2026 24:36
BRIEF-Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Otsuka Holdings Co., Ltd. 4578.T:
OTSUKA HOLDINGS CO., LTD. - ZIPALERTINIB PLUS CHEMOTHERAPY DEMONSTRATES 6-MONTH MEDIAN PROGRESSION-FREE SURVIVAL BENEFIT IN REZILIENT3 PHASE 3 TRIAL IN FIRST-LINE EGFR EXON 20 INSERTION MUTATION NON-SMALL CELL LUNG CANCER
Source text: ID:nTSum82b6b
Further company coverage: 4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug